Axon Enterprise (NASDAQ:AXON) Given New $550.00 Price Target at Northland Securities

Axon Enterprise (NASDAQ:AXON - Get Free Report) had its price objective hoisted by Northland Securities from $365.00 to $550.00 in a note issued to investors on Monday,Benzinga reports. The firm currently has an "outperform" rating on the biotechnology company's stock. Northland Securities' target price would suggest a potential downside of 10.73% from the company's previous close.

Other research analysts also recently issued research reports about the company. Jefferies Financial Group started coverage on Axon Enterprise in a research note on Wednesday, July 17th. They set a "buy" rating and a $385.00 price target on the stock. JMP Securities lifted their target price on shares of Axon Enterprise from $430.00 to $500.00 and gave the company a "market outperform" rating in a report on Thursday, October 31st. Robert W. Baird upped their price target on shares of Axon Enterprise from $440.00 to $460.00 and gave the company an "outperform" rating in a research report on Monday, November 4th. Bank of America began coverage on shares of Axon Enterprise in a research note on Wednesday, July 17th. They issued a "buy" rating and a $380.00 price objective on the stock. Finally, The Goldman Sachs Group increased their target price on shares of Axon Enterprise from $385.00 to $441.00 and gave the stock a "buy" rating in a research note on Wednesday, October 23rd. Two research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. According to data from MarketBeat.com, Axon Enterprise currently has an average rating of "Moderate Buy" and a consensus price target of $427.83.

Axon Enterprise Stock Up 2.1 %

AXON stock traded up $12.96 during midday trading on Monday, reaching $616.14. 1,792,632 shares of the company were exchanged, compared to its average volume of 544,227. The company has a market cap of $46.56 billion, a price-to-earnings ratio of 158.14, a price-to-earnings-growth ratio of 15.15 and a beta of 0.94. The company has a debt-to-equity ratio of 0.35, a quick ratio of 2.52 and a current ratio of 2.88. Axon Enterprise has a 1-year low of $216.73 and a 1-year high of $624.84. The stock's 50-day simple moving average is $414.16 and its 200 day simple moving average is $347.59.

Insiders Place Their Bets

In other news, Director Caitlin Elizabeth Kalinowski sold 450 shares of Axon Enterprise stock in a transaction that occurred on Wednesday, August 21st. The shares were sold at an average price of $373.03, for a total transaction of $167,863.50. Following the completion of the sale, the director now directly owns 7,379 shares in the company, valued at approximately $2,752,588.37. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Axon Enterprise news, CEO Patrick W. Smith sold 80,300 shares of the firm's stock in a transaction dated Friday, August 23rd. The shares were sold at an average price of $371.78, for a total transaction of $29,853,934.00. Following the completion of the transaction, the chief executive officer now directly owns 3,015,366 shares in the company, valued at approximately $1,121,052,771.48. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Caitlin Elizabeth Kalinowski sold 450 shares of the company's stock in a transaction dated Wednesday, August 21st. The shares were sold at an average price of $373.03, for a total transaction of $167,863.50. Following the completion of the sale, the director now directly owns 7,379 shares in the company, valued at $2,752,588.37. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 369,172 shares of company stock worth $136,270,842. Corporate insiders own 6.10% of the company's stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. PFG Investments LLC boosted its stake in shares of Axon Enterprise by 0.6% during the 3rd quarter. PFG Investments LLC now owns 3,872 shares of the biotechnology company's stock worth $1,547,000 after purchasing an additional 25 shares during the last quarter. Gladstone Institutional Advisory LLC grew its stake in Axon Enterprise by 1.6% in the 3rd quarter. Gladstone Institutional Advisory LLC now owns 1,641 shares of the biotechnology company's stock worth $656,000 after acquiring an additional 26 shares during the period. Mather Group LLC. raised its holdings in Axon Enterprise by 3.7% in the 3rd quarter. Mather Group LLC. now owns 759 shares of the biotechnology company's stock valued at $303,000 after acquiring an additional 27 shares during the last quarter. King Luther Capital Management Corp lifted its stake in shares of Axon Enterprise by 0.3% during the 3rd quarter. King Luther Capital Management Corp now owns 10,474 shares of the biotechnology company's stock worth $4,185,000 after purchasing an additional 34 shares during the period. Finally, CWM LLC boosted its holdings in shares of Axon Enterprise by 1.3% during the third quarter. CWM LLC now owns 2,856 shares of the biotechnology company's stock worth $1,141,000 after purchasing an additional 36 shares during the last quarter. 79.08% of the stock is currently owned by institutional investors and hedge funds.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.